Alexion Pharmaceuticals (ALXN) PT Lowered to $170.00

Alexion Pharmaceuticals (NASDAQ:ALXN) had its price objective cut by stock analysts at Citigroup from $173.00 to $170.00 in a report released on Friday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Citigroup’s price target would suggest a potential upside of 56.73% from the stock’s current price.

ALXN has been the subject of several other research reports. TheStreet downgraded shares of Alexion Pharmaceuticals from a “b-” rating to a “c+” rating in a research report on Friday, November 10th. BidaskClub raised shares of Alexion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, December 27th. Zacks Investment Research raised shares of Alexion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $144.00 price objective for the company in a research report on Tuesday, October 31st. Credit Suisse Group reaffirmed a “buy” rating and set a $166.00 price objective on shares of Alexion Pharmaceuticals in a research report on Tuesday, December 12th. Finally, Raymond James Financial reaffirmed an “outperform” rating and set a $130.00 price objective (down previously from $178.00) on shares of Alexion Pharmaceuticals in a research report on Thursday, January 4th. They noted that the move was a valuation call. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and twenty-one have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $153.86.

Shares of Alexion Pharmaceuticals (ALXN) opened at $108.47 on Friday. The company has a market cap of $26,172.44, a P/E ratio of 48.42, a PEG ratio of 0.98 and a beta of 1.16. Alexion Pharmaceuticals has a 52-week low of $96.18 and a 52-week high of $149.34. The company has a current ratio of 2.96, a quick ratio of 2.51 and a debt-to-equity ratio of 0.35.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings data on Thursday, February 8th. The biopharmaceutical company reported $1.48 EPS for the quarter, topping the consensus estimate of $1.27 by $0.21. The company had revenue of $909.70 million during the quarter, compared to the consensus estimate of $880.38 million. Alexion Pharmaceuticals had a net margin of 14.57% and a return on equity of 12.55%. The company’s quarterly revenue was up 9.5% on a year-over-year basis. During the same quarter last year, the firm posted $1.26 EPS. research analysts expect that Alexion Pharmaceuticals will post 4.82 earnings per share for the current year.

In other Alexion Pharmaceuticals news, CEO Ludwig Hantson sold 2,553 shares of Alexion Pharmaceuticals stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $121.63, for a total transaction of $310,521.39. Following the transaction, the chief executive officer now directly owns 36,172 shares of the company’s stock, valued at approximately $4,399,600.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Paul J. Clancy sold 6,079 shares of Alexion Pharmaceuticals stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $116.31, for a total transaction of $707,048.49. Following the transaction, the chief financial officer now directly owns 95,093 shares in the company, valued at $11,060,266.83. The disclosure for this sale can be found here. In the last three months, insiders sold 28,930 shares of company stock valued at $3,378,199. 4.35% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of ALXN. Valeo Financial Advisors LLC purchased a new position in Alexion Pharmaceuticals during the 3rd quarter worth $147,000. Dupont Capital Management Corp purchased a new position in Alexion Pharmaceuticals during the 3rd quarter worth $156,000. BT Investment Management Ltd purchased a new position in Alexion Pharmaceuticals during the 3rd quarter worth $165,000. Beacon Investment Advisory Services Inc. purchased a new position in Alexion Pharmaceuticals during the 3rd quarter worth $201,000. Finally, Invictus RG purchased a new position in Alexion Pharmaceuticals during the 3rd quarter worth $202,000. 94.04% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: This piece was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece on another site, it was copied illegally and republished in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://sportsperspectives.com/2018/02/09/alexion-pharmaceuticals-alxn-pt-lowered-to-170-00.html.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply